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Chamieai names 
SDZ208911: N-~(8u)-2,6-dimethylergohne-B-yl]-2,2- 
djethyipropanamide 
SDZZO8912: N-[(8cY)-2-chtoro-6-methylergoline-&yl]- 
2,2-diethylpropanamide 
The current endotherm 
receptor classification: 
time for reconsideration? 
~iiern A. Bax and Pramod R. Saxena 
The possible involvement of endothelins in a variety 
of diseases has attracted the attention of many 
pharmacologists in search of a novel therapeutic 
approach. The rapid development of ~ndothelin 
research has resulted in the molecular 
characterization and pharmacological recognition of 
ET, and ET, receptors, and in the development of 
compounds selective for these receptors. However, 
the characterization ofreceptors in various assays 
has shown that a number of effects are mediated 
by receptors that do not fit the present criteria for 
ETA or ET, receptors. In this article, Willem Bax 
and Pramod Saxena address endothelin receptors 
in general, and atypical receptors in particular. 
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Endothelin was discovered and recognized as a potent 
vasoconstrictor peptide only six years ago’. Threedistinct 
endogenous endothelin isoforms endothelin 1 (ET-I), 
ET-2 and ET-3 are cleaved from the endothelin precursors 
big-ET-l, big-ET-2 and big-ET-3 by an endothelin con- 
verting enzyme. Increased concentrations of endothelins 
have been observed after myocardial infarction, in 
atherosclerosis, (pulmonary) hypertension, migraine and 
many other diseasesr. Although recent advances towards 
the elucidation of the molecular structure of endothelin 
converting enzymes” will undoubtedly be followed by 
the development of inhibitors of endothelin converting 
enzymes, efforts have so far primarily been directed to the 
devefopment ofendotheiin receptor antagonists for clini- 
cal purposes. Indeed ET,, and ET, receptors were 
clonedQ, and selective ligands for these receptors have 
been recognized. 
The current criteria for endothelin receptor 
classification 
In general, receptor classification should be based on 
three criteriab? (1) gene nucleotide and amino acid se- 
quence of the receptor protein, (21 ~ptor-eff~t coupling, 
and (3) interaction between receptors and agonists or 
antagonists, Endothelin receptors are currently classified 
by the consensus view of the subcommittee ofthe inter- 
national Union of Pharmacology (IUPHAR), primarily 
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according to the potency order ofendothelin isopeptides, 
but also according to the potency of some antagonists. In
so-calltd type I responses, ET-1 is more potent han ET-3, 
whereas in type II responses, both isopeptides have simi- 
lar potency. In studies applying techniques to express 
cDNA for the cumzntly known endothelin receptors, it was 
established that he type Iand type II responses correspond 
to ET,, and ET, receptors, respectivelp. 
Gene mdeotiffe md amino ticid seqfderlce of t/te 
receptor protein 
ET,% and ET, receptors have approximately 63% amino 
acid homology. Southern blots of the human genomic 
DNA, using cDNA probes for the ET, and ET, receptor 
under low stringency, revealed only two signals, probably 
corresponding to human ET,a and ET, receptor genes. 
Thus, it appeared that other endothelin receptors, if exist- 
ent, would probably have a considerably different amino 
acid seyuenceq. However, itshould be noted that although 
amino acid homology may be indicative of pharmaco- 
logical similarity, this is not a general prerequisite. For 
example, 5-HT, u and 5-HT,,, receptors have a clearly dif- 
ferent pharmacological profile for a number of compounds, 
despite a 967 amino acid homology in the transmem- 
brane region. By contrast, SHT,,,, and 5-HT,,, receptors 
are pharmacologically almost indistinguishable, but have 
a relatively moderate 77% amino acid homology in the 
transmembrane region:. 
Recently, the identification of cDNA for a receptor with 
relatively high affinity for ET-3 was reported in Xmyus 
dcrmal melanophores. This receptor had approximately 
50% amino acid homology with ET, and ET, receptors”‘. 
However, it is not yet certain whether it actually 
represented the pu;ative ET, receptor, which is highly 
selective for ET-3 and has been reported in pharma- 
cological studies in bovine endothelial cellsI’, or whether 
it represented the Xt~q~s variant of, for example, ET, 
receptors. Because of the scarcity of functional correlates 
and the lack of selective ET, receptor ligands other than 
ET-3, ET, receptors will not be discussed in further 
detail. 
Second messenger mechnnisrns 
Both ET, and ET,, receptors have been described to 
be coupled to phosphatidylinositol (4,5)-bisphosphate 
(PtdInsPJ hydrolysis via G protein-coupled phospholipase 
C, and to the generation of inositol phosphates (InsP) and 
diacylglycerol, resulting in an increased concentration of 
intracellular Caz- (Ref. 8). In transfected Chinese hamster 
ovary cells, it was observed that ET,q receptors induced 
accumulation of CAMP, whereas ET, receptors inhibited 
forskolin-stimulated CAMP production’?. However, the 
stimulation of adenylate cyclase, mediated by ET, recep- 
tors, was less efficient han the stimulation of InsP for- 
mation, which raises questions about the physiological 
relevance of adenylate cyclase as a second messenger 
system in these ceW. 
Less is known about transduction of receptors that do 
not resemble the ET, or ET, type. In the follicular mem- 
branes of X~~rq~s Inezlis oocytes, Kumar and co-workers” 
observed endothelin receptors that resemble human ET, 
receptors in their affinity for ET-l, ET-3 and sarafotoxin 
Table 1. The affinity (IN) of endothelin receptor ligands far endothelin ET, and ET, receptors 
ligand ET, ET, Refs 
Ki f&J Ki f&a Kd 
ET-l 3 5, 0 58. 0.9P 0.16, 0.29 0.95, 0.12 1.6. 0.06. 0.44 0.003 4.9,57-61 
ET-3 1000.83.900* 50,150 2.0, 0.13 1.6, 0.06, 0.11 0.014 4.9.57-61 
Sarafotoxin S6b 522 4 
Sarafotoxm S6c 2800 1300 0.29 0.3, 0.12 0.24 5861 
[Ala"" 'jET-1 398 0.25 20 59,61 
BQ123 25.17 13.63 31000.11100 >10000.>100000 285 57-61 
FR139317 1,' 6.3. 13 73003 20000. ~100000 59, 60, 62 
Elcl788 1300 1.2 28 
Ro462005 200,360 160,530 59.60 
Bosentan 65 343 63 
SE209670 04 2.0 15 32 59,64 
EMS182874 63 1600 55000 >10000 59.65 
97139 1 1000 66 
Data obta!net: in ceil hes transfected wrth human or.'bovmeendothelm receptors For I30788 and 97139, only radioligand bIndIng data obtamed m mem- 
braoasare avallablelETL SK-N-MChuman neuroblastomacelllmeWt788l,andA7r5 rataortlcsmooth musclecells(97139J,ET,.humanG~rard~ heart cells\. 
to Ref 59. & values were calculated o approxtmate IC,,,values ET-l. elldothehr 1. ET-3,endothelm 3 
3 8 0 TiPS - Ortohrr tY9.l IVo. 15) 
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She, but exhibit an atypically low affinity for BQ123. 
Activation of these receptors, which were considered 
to be a subtype of ET, receptors (ET,,), resulted in 
mobilization of Ca’+, which was blocked by treatment 
that uncouples gap junctions. By contrast, Ca?+ mobil- 
ization induced by expressed human ET, receptors was 
not sensitive to such treatment. In a further study, 
[9]ET-1 binding to human brain endothelial cells 
revealed a high- and a low-affinity binding site”. The 
high-affinity binding site had the order of affinity 
ET-1 > ET-2 > sarafotoxin S6b > ET-3, which resembled 
the ET,,, receptor and also matched the order of potency 
for InsP accumulation in these cells. The order of 
affinity for the unidentified low-affinity binding site 
(sarafotoxin S6b > ET-2 > ET-1 = ET-31 did not match 
the order of potency for InsP accumulation. Other 
second messenger systems were not examined in the 
latter study. 
Pharmacological characterization of endothelin 
receptors 
The present classification of endothelin receptors 
relies largely on data obtained in functional or radio- 
ligand binding experiments” In addition to the fre- 
quently applied potency order of ET-1 and ET-3, a 
number of synthetic compounds has been identified 
with selectivity for ET, or ET, receptors (Table 1). 
The pharmacological characterization of endothelin 
receptors i  hampered by several pitfalls: 
(1) Endothelin peptides can be internalized after 
binding to the receptorI?, and hence may not be available 
for ligand-receptor competition. 
(2) The formation of ligand-receptor complexes with 
different dissociative behaviours depending on the ligand 
used may result in complicated receptor kineticsl~J7. 
(3) Endothelin receptors may downregulate’H or desen- 
sitize rapidly, possibly resulting in a differentially altered 
response to various endothelin peptides19. 
Responses mediated by endothelin receptors 
Typical ET, receptors 
ET,, receptors have often been found to mediate con- 
tractile responses inisolated smooth muscle preparations. 
The involvement of ET,, receptors was typically established 
on the basis of the relative order of potency of ET-l and 
ET-3, and on the inability of ET, receptor-selective com- 
pounds (for example, sarafotoxin S6c or [Ala’JJlJ”]ET-1) 
to act as agonists. Moreover, both BQ123 and FR139317 
were generally used as ET, receptor antagonists. Typical 
examples of preparations with ET, receptors that me- 
diate contractions include the rat?” and guinea-pig-?’ aorta 
(Table 2). 
Typical ET, receptors 
ET, receptors were originally considered as ‘vasodilator 
receptors’ in contrast to the vasoconstrictor ET, receptors. 
Warner and colleagueGshowed that ET-3 and ET-l were 
equipotent as vasodilators, whereas ET-1 had been shown 
Table 2. Examples of studies in which the response was concluded to be mediated via an endothelin ET,, receptor 
Species Tissue and response Characterization criteria 
Agonist Antagonist against ET-l 
Rat Thoracic aorta contraction ET-1 > ET-3; [Ala’ 3 “J”]ET-1: no effect PA, 80123: 6.93 
Rabbit Carotid artery contraction ET-l > ET-3; pA, 60123: 6.8 
(Ala~J1~.~5]ET-1 and sarafotoxin S6c: no effect 
ET-l > ET-3; sarafotoxin S6c: no effect pK, 80123: 7.5 
Guinea-pig Pulmonary artery contraction ET-1 > ET-3 pA, FR139317: 6.65 
Sarafotoxin S6c: no effect pK, BL1123: 6.7 
Aorta contraction Sarafotoxin S6c: no effect pK, K!123: 7.1 
ET-1 > ET-3; pA, 80123: 7.4 
[Alal.3.“Jb]ET-l and sarafotoxin S6c: no effect 
Iliac artery contraction ET-1 > ET-3; sarafotoxin S6c: no effect pK,, BOi23: 6.6-7.2 
pA, FR13931i: 5.82 
Goat Cerebral artery contraction ET-1 > ET-3 ph;, 80123: 7.43 
Human Coronary artery contraction ET-l > ET-3 pA, B[1123: 6.4-7.47 
Omental artery contraction ET-l > ET-3 pA, 80123: 7.09 
Pulmonary artery contraction Sarafotoxin S6c: no effect pK,, 60123: 6.2-6.8 
ET-l, endothelin 1: ET-3, endofhelin 3. 
Ref. 
20 
30 
30 
24 
67 
21 
21 
49 
49 
68 
68 
34 
52 
26 
21 
Tit’s - Chrhrr l’lY4 (Vd. IS) 3 8 1 
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Table 3. Examples ofstudies in which the response was concluded to be mediated via an endothelin ET, m?PtOr 
Species Tiiue and response Characterization criteria Ref. 
Agonist Antagonists 
Rat Aorta relaxation IRL1620 BQ123: noeffect (lRL1620) 69 
Rabbit Pulmonav artery contraction ET-1 = ET-3; 60123: no effect (ET-l. ET-3. [Ala’3~“~‘5]ET-l) 30 
[Ala13.” IslET- and sarafctoxin S6c 30 
ET-1 = ET-3: WI3020 BQ123: no effect (BR3020) 70 
ET-1 = sarafotoxin S6c 60123 and PD124893: no effect (ET-1 J 43 
PA, B0788: 8.4 (603020) 29 
Jugular vein contraction ET-l = ET-3; 60123: no effect (ET-l, ET 3. [Ala’.3.1~~15]ET-1) 30 
[Ala13 1’ IslET- and sarafotoxin S6c 30 
Saphenous vein contraction ET-1 = ET-3; sarafotoxin S6c 60123: no effect (sarafotoxin S6c. ET-l) 24 
Guinea-pig Bronchus contraction Sarafotoxin S6c 60123: no effect lsarafotoxin S6c. ET-l) 21 
Trachea contraction ML1620 71 
ET-l = ET-3 FR139317: no effect {ET-l, ET-2. ET-31 67 
Pig Pulmonary artery relaxation (Alal.3 11,‘5]ET-1 72 
El03020 70 
Canine Coronary artery constriction Sarafotoxin S6c 60123: no effect (sarafotoxin S6c) 44 
Human Bronchus contraction Sarafotoxm S6c 60123: no effect (sarafotoxin S6c. ET-l) 21 
“The agmst agamst which the antagomst was studied is indicated between brackets. ET-l. endothelin 1; ET-Z. endothelin 2: ET-3. endothelin 3. 
to be 2D-fold more potent as a vasoconstricto+. Thus, the 
involvement of ET, receptors was first established on the 
basis of equipotency ofET-1 and ET-3. Later, it was shown 
that ET, receptors were also involved in smooth muscle 
contraction i blood vessels uch as the rabbit saphenous 
vein” and in the guinea-pig bronchuszl. In these tissues, 
84123 failed to inhibit the contractile responses, and 
sarafotoxin S6c was observed to produce contraction. 
Other studies used [Ala’JJ’J~IET-1, IRL162D and DQ3020 
as agonists (Table 3). Until recently, only IRL1038 was 
available as a selective ET, receptor antagonisWh. 
Unfortunately, theaffinity for ETsreceptors was reported 
to be highly variable between batches, and data obtained 
with this compound should be considered with caution?;. 
However, the recent development of the potent and 
selective ET, receptor antagonist BQ788 provided a 
novei tool to study the involvement of ET, receptor+ 
(Table 3). 
Mixed ET, and ET, receptor populations 
In the guinea-pig trachea, BQ123 was a weak antagon- 
ist of ET-l-induced contraction, sarafotoxin S6c was a par- 
tial agonist and the contractile ffect of sarafotoxin S6c 
was resistant to antagonism by 84123 (Ref. 21). Thus; it 
was concluded that both ET, and ET, rcccptors mediated 
contractile responses in the guinea-pig trachea”. Vaso- 
constriction in the isolated perfused rat kidney was also 
mediated by both ET, and ET, receptors*9. In this 
preparation, BQ123 and FR139317 caused only partial 
attenuation of ET-l-induced contractions, whereas the 
nonse!ective ET, and ET, receptor antagonist PIl145065 
completely abolished the responses to ET-1 (Ref. 29). 
Even in blood vessels uch as the rabbit saphenous 
vein?4 and pulmonary artery30 that had previously been 
considered to contract via ET, receptors exclusively, a 
coexisting ET, receptor mediating vasoconstriction has 
been demonstrated by showing that 84123 attenuated 
part of the concentration-response curve to ET-l in both 
vessels, despite an observed equipotency of ET-l and 
ET-3 (Refs 31,321. The presence of ET, receptors inthe rab- 
bit pulmonary artery has been confirmed by radioligand 
membrane-binding studie$ (Table 4). 
Atypical endothelin responses observed using ET, 
receptor-selective compounds 
A number of preparations exhibited an agonist order 
of potency of ET-I >ET-3, which would imply the in- 
volvement of ET, receptors. However, BQ123 was found 
to inhibit ET-3-induced contractions ubstantially more 
potently than ET-l-induced contractions, uggesting the 
presence of different receptors?” (Table 5). Pierre and 
Clarke”” suggested that the BQ123-sensitive contractions 
to ET-3 in the rat isolated renal artery were mediated via 
ET,, receptors, whereas the relatively BQ123-insensitive 
3 8 2 Tip.5 -October 1994 (Vol. 15) 
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Table 4. Examples of studies in which the response was concluded to be mediated via a mixed population of endothelin 
ET, and ET, receptors 
Species Tissue and response 
Agonist 
Characterization criteria 
Antagonir 
Ref. 
Rat 
Rabbit 
Kidney perfusion ET-1 = ET-3 = sarafotoxin S6b = 80123: little effect (ET-l. sarafotoxin S6b) 73 
sarafotoxin S6c 
Sarafotoxin S6c BQ123 and FR139317: partial inhibition (ET-I) 29 
PD145065: complete inhibition (ET-l) 29 
Pulmonary artery contraction Sarafotoxin S6c > ET-1 80123: antagonist (high concentrations ET-l) 32 
Sarafotoxin S6c: no effectb PA, BQ123: 6.6 (ET-1)b 32 
Saphenous vein contraction Sarafotoxin S6c > ET-1 = ET-3 10~~ BQ123: antagonist (high 32 
concentrations ET-l) 
Guinea-pig Trachea contraction Sarafotoxin S6c 811123: no effect (sarafotoxin S6c) 21 
pk’, BQ123: 6.2 (ET-l) 21 
Human Internal mammary artery Sarafotoxin S6c: partial BQ123 and FR139317: antagonists (ET-l] 51 
contraction agonist 
aThe agonist against which the antagonist was studied is indicated between brackets. Wesponse determined after 30 min pretreatment with sarafotoxin 
S6c. ET-l. endothelin 1; ET-3. endothelin 3. 
ET-l-induced contractile responses were mediated via 
non-ET, receptors. Although this is a plausible expla- 
nation with regard to the antagonist, itis yet unclear why 
ET-3 recognizes an ET,, receptor that is not recognized by 
ET-I. Similarly, in the goat cerebral artery, contractile re 
sponses induced by sarafotoxin S6b were antagonized 
more potently by 84123 than those induced by ET-1 
(Ref. 34) (Table 5). It has been argued that the reversibility 
of receptor binding of ET-l is different from that of ET-3 
or sarafotoxin S6b, and that this could account for the dif- 
ferences in antagonist potencies against hese agonists9 
However, this does not explain the biphasic antagonism 
of sarafotoxin S6b-induced contractions of the human 
saphenous vein by BQ123 (Ref. 361, or the biphasic dis- 
placement of binding with 3OpM [i%arafol 3xin S6b by 
BQl23 in the media of human coronary artcries37. Fur- 
thermore, it should be noted that in other investigations, 
the antagonist potency did not differ between these par- 
ticular agonists3Ho, rwas even higher against ET-1 than 
against the other agonisP,‘r. Thus, although the possi- 
bility of interference by complex endothelin receptor 
kinetic+I9 should not entirely be disregarded, it appears 
that ET-1 on the one hand, and sarafotoxin S6b and ET-3 
on the other hand, may exert their effects via different 
receptors that do not fit the current classification of ET, 
and ET, receptors. 
Atypical endothelin responses observed using ET, 
receptor-selective compounds 
Warner and colleagues4” observed an ETs receptor that 
mediated constriction of the rabbit pulmonary artery and 
rat stomach strip that was relatively insensitive to the non- 
selective endothelin receptor antagonist PD142893. By 
contrast, I’D142893 potently antagonized the ET, recep- 
tor-mediated vasodilator effect in the perfused mesentery, 
which indicated receptor heterogeneity among ET, recep- 
tors43. In addition, a study in swine pulmonary blood 
vessels revealed differences between ET, receptors 
mediating contraction and endothelium-dependent 
relaxation35. Only receptors mediating endothelium- 
dependent relaxation were sensitive to antagonism by 
the ET, receptor antagonist lRL1038 (Ref. 25). However, 
as mentioned above, it should be noted that questions 
have arisen over the use of IRL1038 as an ET, receptor 
antagonistrr, and these experiments need verification 
using alternative antagonists with affinity for ET, recep- 
tors. Radioligand binding studies in canine coronary 
artery membranes also indicated the possibility of ET, 
receptor subtype@. These binding sites had either high or 
low affinity for both ET-1 and ET-3. In addition, the high- 
affinity ET, site showed high affinity for sarafotoxin S6c, 
but not for BQ123, whereas the low-affinity ET, site had 
moderate affinity for both sarafotoxin S6c and BQ123. 
Coronary vasoconstriction i duced by sarafotoxin S6c 
was insensitive to BQ123, indicating involvement of the 
high-affinity ET, site. No functional correlate for the low- 
affinity ET, site is known at presenP. In the rat left 
atrium, equipotent contractile responses to ET-l, ET-2, 
ET-3 and sarafotoxin S6b were observed, irdicaiing 
the involvement of ET, receptors. However, the in- 
effectiveness of the ET, receptor agonists [Ala’JJJ51ET-1 
and sarafotoxin S6c would suggest he involvement of 
receptors other than conventional ET, receptors4s. Simi- 
larly, Xeiroprls I~cvis liver membranes revealed abinding 
site with identical affinity for ET-l and ET-3. As expected 
for ET, receptors, BQ123 was ineffective in displacing 
TiPS -October 1994 ‘Vol. 15) 383 
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cable 5 Examples of studies in which the response was concluded to be mediated by a single or mixed WEptOr 
population consisting of receptors characterized as partly atypical or as subtypes of endothelin ET, and/or ET, receptors 
Species Tissue and response Observations Refs 
ET, receptor-selective compounds 
Rat Aorta contraction BQ123 more potent versus ET-3 than versus ET-l; [Alar~3~lr~r5]ET-l: no effect 20 
\/as deferens increased twitch BQ123 and PO142893 more potent versus ET-3 and sarafotoxin S6b than versus ET-l; 56,74 
sarafotoxin S6c: no effect 
Goat 
Human 
Rat 
Pig 
Cerebral artery contraction BQ123 more potent versus sarafotoxin S6b than versus ET-l 34 
Small omental vein contraction 811123 more potent versus ET-3 than versus ET-1 26 
BQ123 more potent versus high than versus low concentrations of ET-3 26 
IRL1038 no effect against ET-F; sarafotoxin S6c: no effect 26 
Coronary artery contraction BQ123 more potent versus ET-3 than versus ET-1 52 
BQ123 and FR139317 more potent versus sarafotoxin S6b than versus ET-l; 53 
[Alar.3.“.rS]ET-l: no effect 
Saphenous vein contraction BQ123 more potent versus sarafotoxin S6b than versus ET-1 36 
BQ123 more potent versus high than versus low concentrations of sarafotoxin S6b 36 
Umbilical artery contraction BQ123 more potent versus sarafotoxin S6b than versus ET-1 54 
ET, receptor-selectiue compounds 
Stomach strip contraction Contraction to sarafotoxin S6c (more potent than ET-l) weakly antagonized 43 
by PO1 42893 
Perfused mesentery dilatation Dilatation to sarafotoxin S6c (equipotent ET-l) strongly antagonized by PO142893 43 
Atrium contraction ET-l, ET-3, sarafotoxin S6b equipotent; sarafotoxin S6c and [Alal.s,rl rs]ET-1 no effect 45 
Pulmonary vein contractiona lsopeptide nonselective receotor, resistant to IRL1038 25 
Pulmonary artery relaxationa lsopeptide nonselective receptor, sensitive to IRL1038 25 
Coronary artery contraction Sarafotoxin SGc-sensitive receptor recognizes ET-3, but not ET-1 or sarafotoxin S6b 48 
Sarafotoxin S6c and [Alar.3.” ISJET-1 sensitive receptor [pK, 80123: ==5 LET-l]], 49 
and another receptor resistant to BQ123 
aThe receptor affmrty and selectivity for ET, receptors of IRL1038 have been described to be highly variable. Therefore, these data must be interpreted 
with caution? 
[rEI]ET-1 labeling of this site, but sarafotoxin S6c was also 
ineffective, suggesting the presence of a subtype of ET, 
receptors*. 
Other atypical end&h&n responses 
The nature of endothelin receptors that mediate con- 
traction of the porcine coronary artery is still contro- 
versial, but part of the receptor population does not 
appear to correspond to either ET, or ET, receptors. Ihara 
and co-workers47 observed ET-l-induced contractile re 
sponses that were sensitive to antagonism by BQ123 
(PA, = 7.4) and thus considered to be mediated by ET, 
receptors. The small 84123 nonsensitive part of the con- 
centration-response curve to ET-1 was assigned to be 
mediated by ET, receptors”. Further shldies agreed on 
the ET,A receptor component on the basis of the agonist 
order of potency, but also observed areceptor that recog- 
nized sarafotoxin S6c and ET-3, but not ET-I and sarafo- 
toxin S6b (Ref. 48). Later, it was shown that the contrac- 
tile effects of both sarafotoxin S6c and [AlarJJrJ5]ET-1 were 
likely to be mediated via the same ET, receptor, whereas 
a non-ET,, non-ET, type of receptor contributed to the 
contractile response induced by ET-I (Ref. 49) (Tabie 5). 
Endothelin receptors in human bload vessels 
Endothelin receptors mediating contractions inhuman 
blood vessels were recently reviewed by Davenport and 
Maguirej”. Although the contractile responses may be 
mediated via typical ET, receptors50 (perhaps in addition 
to ET, receptorss’), there are several reports focusing on 
non-ET,,, non-ET, receptors in human blood vessels. 
In parallel with the rat aorta20 and the goat cerebral 
artery” (Table 51, BQ123 has been observed to be more 
potent against ET-3-and sarafotoxin SGb-induced contrac- 
tions than against ET-l-induced contracti!e responses in 
the human isolated saphenous vein%, coronary arterys*,ss, 
umbilical artery54 and in small omental vein+. Recent 
data obtained in the human isolated coronary artery 
REVIEWS 
suggest hat the same discrepancy between ET-l- and 
sarafotoxin SGb-induced contractile responses is also 
observed with other ET, receptor antagonists, uch as 
FR139317 (Ref. 53). 
It is unclear whether the ET, receptor plays a signifi- 
cant role in vasoconstriction of human blood vessels. 
Indeed, the endogenous ligand ET-3 is a less potent vase- 
constrictor agonist han ET-l. Moreover, both ET, receptor 
agonists 843020 and [Ala~JJ*J5IET-l hardly contracted 
the human isolated coronary arteryso. However, sarafo- 
toxin S6c induced contractile responses in some (but 
not all) coronary arte*O, internal mammary artery51 or 
saphenous vein55 segments. Although this may be due to 
a relatively low ET, receptor density54 these observations 
could also be related to the isopeptide nonselective ET, 
receptors, with low affinity for the ET, receptor agonists 
[AlalJJJ5lET-1 or sarafotoxin S6c (Refs 45,461. 
Concluding remarks 
The above-mentioned studies indicate that the current 
ET, and ET, endothelin receptor classification will have 
to be extended. A number of responses fit the present cri- 
teria for the ET, receptor, but evidence indicating that 
ET, receptor antagonists are sometimes more potent 
against ET-3 (Refs 20,26,52,56) or sarafotoxin S6b (Refs 
34,36,53,54,56) than against ET-l suggests further hetero- 
geneity of e:?dothelin receptors. These receptors may be 
classified a2 subtypes of the ET, receptor, since ET, recep 
tor antagonists are moderately or highly potent in these 
assays and ET, receptor agonists are usually inactive 
(Table 5). However, since it has only been possible to 
detect his heterogeneity in assays in which both recep- 
tors mediate the same effect, a detailed pharmacological 
analysis of the individual receptors has not yet been estab- 
lished, and a conclusive classification of these receptors i
therefore best postponed. 
ET, receptors also appear to be heterogeneous since the 
relaxant but not the contractile responses were antagon- 
ized by PD142893. However, only the affinity for the 
antagonist should be used as a criterium for pharmaco- 
logical receptor classification, and not whether the recep 
tor mediates contraction or relaxatio@. In view of the 
effect of ET, receptor agonists and the ineffectiveness of 
BQ123, it would appear that these receptors may be des- 
ignated ET,, (PD142893-sensitive) and ET,, (PD142893- 
insensitive) receptor subtypes. Whether additional ET, 
receptor subtypes exist, for example, in canine coronary 
artery@, or whether other atypical observations are related 
to the proposed ET,, or ETsz receptor subtypes, remains 
to be resolved (Table 5). 
The currently available data are not yet sufficient o 
provide a conclusively extended endothelin receptor 
nomenclature. Indeed, additional data on second mess- 
enger mechanisms and possibly on the sequence of the 
corresponding DNA are eagerly awaited, and the use of 
more agonists and antagonists in functional studies is 
vita16J. For now, it should be noted that, in particular, the 
current basic criteri:.m of the potency difference of ET-l 
and ET-3 should be applied with the utmost restraint. In 
some smooth muscle preparations, ET-l is clearly more 
potent han ET-3, suggesting the involvement of ET, re- 
ceptors. However, considering the observed antagonist 
potency differenceszt*Ls*, the two peptides may in fact 
induce contractions via different receptors (Table 5). In 
other tissues, ET-1 and ET-3 are equipotent, suggesting 
the involvement of ET, receptors. However, ET, receptor 
agonists may in some cases be inactive45, and detailed 
analysis using ET, receptor antagonists has been used to 
demonstrate the presence of an additional ET, recep- 
toPJ*. Given the relatively incomplete understanding of 
endothelin receptors and the limited number of selective 
receptor ligands, the use of a wide spectrum of both agon- 
ists and antagonists i required for endothelin receptor 
characterization. The nonpeptide receptor antagonists 
that are now becoming available will certainly help the 
process towards a conclusive, more detailed endothelin 
receptor classification. 
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Chemioal names 
BQ123: cyc(DTrp-D&p-Pro-Dval-Leu) 
843020: N-acetyl-[Ala~~~~jlendothelin-1(6-21) 
FR139317: 2(R)-[2(R)-(2(s)-l[l-(hexahydro-lH- 
azepinyl)lcarbonyllamino-4methylpentanoyl)- 
amino-3-[3-(l-methyl-lH-indolyl)lpropionylJ- 
amine3-(2-pyridyl)propionic acid 
IRL1620: Suc-[GluU,Ala11~~~lendothelin-l@-21) 
IRL1038: [Cys~~~~~lendothelin-l(ll-21) 
PD145065: acetyl-(5H-dibenzyl[n,dlcycloheptane- 
lO,ll-dihydro-glycinej-~Leu-rasp-~11~~lle-~_Trp 
PD142893: acetyl-(3,3-o-diphenylalanine+Leu- 
LAsp-Llle-LIle-LTrp 
BQ7813: N-cis-2,6-dimethylpiperidinocarbonyl-L-y- 
methylleucyl-o-l-methoxy-carbonyltryptophanyl- 
o-norleucin 
Ro462005: 4-tert-butyl-N-[6-(2-hydroxy-ethoxyj-5- 
(3-methoxy-phenoxyl-4-pyrimidinyll-benzene 
sulphonamide 
SB209670: (+)-(ls,2~,3s)-3-(2-carboxymethoxy-4- 
methoxyphenylk1-(3,4-methylenedioxyphenyl)-5- 
(prop-1-yloxykindane-2-carboxylic acid 
BMS182874: 5-(dimethylamino)-N-(3,4-dimethyl- 
isoxazolyl)-1-naphthalenesulphcn~amide 
97139: 27-O-3-[2-(3-carboxy-acryloyl-amino)-5-hy- 
droxqrphenyllacryloyloxy-myricerone sodium salt 
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